Work

CopperNostics—Here We Are Now, Entertain Us!

Year: 2026

Type: article

Abstract: Diagnosis and endoradiotherapy using copper radioisotopes—defined as Theranostics or, more specifically, CopperNostics—have the potential to play a prominent role in modern precision medicine, as demonstrated by the FDA approval of [64Cu]Cu-DOTA-TATE (Detectnet). In this review we highlight current developments in the production, radiochemical purification, quality control, availability, logistics, and regulatory hurdles of the most relevant copper radioisotopes, 60Cu, 61Cu, 62Cu, 64Cu, and 67Cu, for nuclear medicine. Radiopharmaceuticals based on their application in registered clinical trials, either as molecular imaging agents, companion diagnostics or therapeutic agents, are also presented addressing unmet medical needs.

Source: Pharmaceuticals

DOI: 10.3390/ph19020321

Authors: Santiago Andrés Brühlmann, Martin Walther, Klaus Kopka, Martin Kreller, Oliver C. Kiss

Institutions: Helmholtz-Zentrum Dresden-Rossendorf, Technische Universität Dresden

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,499